Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (February 2015)
17 slides from Cynata Therapeutics's investor presentation, Feb 23, 2015
Slide 1: A Next Generation Stem Cell Company
For personal use only A Next Generation Stem Cell Company Dr Ross Macdonald, CEO, Cynata Therapeutics Limited February, 2015 Copyright and Confidential
Slide 2: Important information
Important information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 3: Cynata Therapeutics Ltd Key Facts
Cynata Therapeutics Ltd Key Facts For personal use only ASX: CYP Commenced Operations: November, 2013 Market Cap (20 Feb 15): A$58m Shares on Issue: 66.0m Cash (30 Dec 14): A$6.2m (~24 months runway) Number of shareholders: ~1150 Business focus: Regenerative medicine: mesenchymal stem cells Major ho
Slide 4: Regenerative Medicine
Regenerative Medicine For personal use only
Slide 5: Why are Mesenchymal Stem Cells Important?
Why are Mesenchymal Stem Cells Important? For personal use only Mesenchymal Stem Cell (MSC) therapies are here and now: Spinal cord injury Neurodegenerative diseases (eg MS) Eye diseases (eg AMD) Chronic wounds Stroke Myocardial infarction (heart attack) Graft-versus-host disease (GvHD) Bone fractur
Slide 6: Cynata's Stem Cell Manufacturing Breakthrough
Cynata’s Stem Cell Manufacturing Breakthrough For personal use only • Cynata recently announced the validation of its CymerusTM MSC manufacturing technology for therapeutic scale-up: so what? • Currently, commercial-scale manufacture of MSC products is a major practical & regulatory challenge – Dono
Slide 7: Cymerus: World-first MSC Manufacturing Technology
Cymerus : World-first MSC Manufacturing Technology TM For personal use only • Completion of tech transfer at Waisman Biomanufacturing: GMP process development, scale- up, validation, documentation From the lab bench….to: • Confirmation that the CymerusTM process can be scaled-up, enabling reproducib
Slide 8: Cynata's Stem Cell Manufacture (Cymerus)
Cynata’s Stem Cell Manufacture (Cymerus™) For personal use only Unlimited 1 expansion 1 1022 capacity • No more cottage industry: commercial scale manufacture • Unlimited MSC stem cell doses from single, one-time donor • Reproducible, clinical grade premium quality MSCs • Consistent quality = consis
Slide 9: Manufacturing issues attracting global attention
Manufacturing issues attracting global attention For personal use only “[lower] number of MSC expansion passages could be correlated to both better response and better survival” “the most egregious divergence between [commercial and academic MSC products] is the scale of product expansion. The indus
Slide 10: Cynata's Cymerus: Outstanding Pedigree
Cynata’s Cymerus : Outstanding Pedigree TM For personal use only • Inventors include Dr James Thomson • In 1998 derived the first human embryonic stem cell line • 2007 derived human induced pluripotent stem cells • Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field •
Slide 11: Cymerus Critical Limb Ischaemia Study
Cymerus Critical Limb Ischaemia Study TM For personal use only Control CymerusTM cells With treatment
Slide 12: Stem Cell Company Market Valuations
Stem Cell Company Market Valuations For personal use only Company Mkt cap Development stage Partners Cash+ Mesoblast (Aus) $1.3b 5 x P3/P3 ready Teva $150m 1 x filed JCR Pharm Asterias (USA) $154m 1 x Ph1/2 ready nil $6.4m* Cynata (Aus) $27m Manufacturing pending $6.2m validated • Cynata capitalised
Slide 13: Cynata Value Catalysts
Cynata Value Catalysts For personal use only • Recent achievements: – Validated manufacturing scale up and process development (Waisman) – In-licensed clinical grade iPSC line (CDI) – Further PoC study underway (following successful CLI study) – Regulatory review and roadmap – Partnerships (announce
Slide 14: Path to Revenue
Path to Revenue For personal use only • Two routes to monetise the Cymerus™ technology – Make our own stem cell medicines (GvHD and others progressing): confirm efficacy; cheaper, better, faster – Capital efficient license-driven strategy: partner with big pharma/big biotech (in discussions); revenu
Slide 15: Cynata Board and Management
Cynata Board and Management For personal use only Executive Chairman: Dr Stewart Washer Managing Director & CEO: Dr Ross Macdonald VP Product Development: Dr Kilian Kelly Non-executive Director: Dr John Chiplin Non-executive Director and Company Secretary: Mr Peter Webse • A tight team with extensiv
Slide 16: Why Invest Now in Cynata Therapeutics?
Why Invest Now in Cynata Therapeutics? For personal use only • Vibrant and expanding field of stem cell medicine • Global demand for stem cell therapeutics (ageing population) • Innovative technology from established & prestigious centre • Cymerus™ overcomes critical shortcoming in commercial stem c
Slide 17: Thank you for your attention
For personal use only Thank you for your attention Contact details: e: ross.macdonald@cynata.com p: +61 (0) 412 119343
Cynata Therapeutics — Investor Presentation (February 2015) on 6ix